Limits...
Downregulation of Plasma MiR-142-3p and MiR-26a-5p in Patients With Colorectal Carcinoma.

Ghanbari R, Mosakhani N, Asadi J, Nouraee N, Mowla SJ, Yazdani Y, Mohamadkhani A, Poustchi H, Knuutila S, Malekzadeh R - Iran J Cancer Prev (2015)

Bottom Line: In profiling study we found a panel of six plasma microRNAs with significant downregulation.Our results demonstrated that expression levels of plasma microRNA-142-3p and microRNA-26a-5p were significantly downregulated in patients with colorectal cancer when compared to control group.Our findings suggest that downregulation of plasma microRNA-142-3p and microRNA-26a-5p might serve as novel noninvasive biomarkers in the diagnosis of colorectal cancer, although more studies are needed to highlight the theoretical strengths.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, IR Iran ; Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran.

ABSTRACT

Background: Colorectal cancer is one of the most commonly diagnosed cancers and cancer- related death worldwide. Identification of new specific biomarkers could be helpful to detection of this malignancy. Altered plasma microRNA expression has been identified in many cancers, including colorectal cancer.

Objectives: The main objective of this study was to identify the circulating microRNAs with the most expression changes in colorectal cancer patients compared with neoplasm free healthy individuals.

Materials and methods: MicroRNA expression profiling was performed on plasma samples of 37 colorectal cancer patients and 8 normal subjects using microRNA microarray. Quantitative real-time reverse transcription polymerase chain reaction was used to validate the two selected altered microR NAs. Plasma samples from 61 colorectal cancer patients and 24 normal subjects were used in our validation study.

Results: In profiling study we found a panel of six plasma microRNAs with significant downregulation. MicroRNA-142-3p and microRNA-26a-5p were selected and validated by polymerase chain reaction. Our results demonstrated that expression levels of plasma microRNA-142-3p and microRNA-26a-5p were significantly downregulated in patients with colorectal cancer when compared to control group.

Conclusions: Our findings suggest that downregulation of plasma microRNA-142-3p and microRNA-26a-5p might serve as novel noninvasive biomarkers in the diagnosis of colorectal cancer, although more studies are needed to highlight the theoretical strengths.

No MeSH data available.


Related in: MedlinePlus

Area Under Curve of Receiver Operating Characteristic for Microrna-142-3p and Microrna-26a-5p
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581368&req=5

A2329FIG2: Area Under Curve of Receiver Operating Characteristic for Microrna-142-3p and Microrna-26a-5p

Mentions: In order to evaluate the diagnostic value of the miR-142-3p and mir-26a-5p in CRC patients, ROC curve analysis was performed. These data revealed that miR-142-3p can potentially be used as a diagnostic biomarker for distinguishing between CRC patients and normal individuals. The area under the curve (AUC value) for miR-142-3p was 71% with the standard error of 0.059 (P value = 0.002) while the AUC value for miR-26a-5p was 67% with the standard error of 0.06 (P value = 0.014) (Figure 2).


Downregulation of Plasma MiR-142-3p and MiR-26a-5p in Patients With Colorectal Carcinoma.

Ghanbari R, Mosakhani N, Asadi J, Nouraee N, Mowla SJ, Yazdani Y, Mohamadkhani A, Poustchi H, Knuutila S, Malekzadeh R - Iran J Cancer Prev (2015)

Area Under Curve of Receiver Operating Characteristic for Microrna-142-3p and Microrna-26a-5p
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581368&req=5

A2329FIG2: Area Under Curve of Receiver Operating Characteristic for Microrna-142-3p and Microrna-26a-5p
Mentions: In order to evaluate the diagnostic value of the miR-142-3p and mir-26a-5p in CRC patients, ROC curve analysis was performed. These data revealed that miR-142-3p can potentially be used as a diagnostic biomarker for distinguishing between CRC patients and normal individuals. The area under the curve (AUC value) for miR-142-3p was 71% with the standard error of 0.059 (P value = 0.002) while the AUC value for miR-26a-5p was 67% with the standard error of 0.06 (P value = 0.014) (Figure 2).

Bottom Line: In profiling study we found a panel of six plasma microRNAs with significant downregulation.Our results demonstrated that expression levels of plasma microRNA-142-3p and microRNA-26a-5p were significantly downregulated in patients with colorectal cancer when compared to control group.Our findings suggest that downregulation of plasma microRNA-142-3p and microRNA-26a-5p might serve as novel noninvasive biomarkers in the diagnosis of colorectal cancer, although more studies are needed to highlight the theoretical strengths.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, IR Iran ; Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran.

ABSTRACT

Background: Colorectal cancer is one of the most commonly diagnosed cancers and cancer- related death worldwide. Identification of new specific biomarkers could be helpful to detection of this malignancy. Altered plasma microRNA expression has been identified in many cancers, including colorectal cancer.

Objectives: The main objective of this study was to identify the circulating microRNAs with the most expression changes in colorectal cancer patients compared with neoplasm free healthy individuals.

Materials and methods: MicroRNA expression profiling was performed on plasma samples of 37 colorectal cancer patients and 8 normal subjects using microRNA microarray. Quantitative real-time reverse transcription polymerase chain reaction was used to validate the two selected altered microR NAs. Plasma samples from 61 colorectal cancer patients and 24 normal subjects were used in our validation study.

Results: In profiling study we found a panel of six plasma microRNAs with significant downregulation. MicroRNA-142-3p and microRNA-26a-5p were selected and validated by polymerase chain reaction. Our results demonstrated that expression levels of plasma microRNA-142-3p and microRNA-26a-5p were significantly downregulated in patients with colorectal cancer when compared to control group.

Conclusions: Our findings suggest that downregulation of plasma microRNA-142-3p and microRNA-26a-5p might serve as novel noninvasive biomarkers in the diagnosis of colorectal cancer, although more studies are needed to highlight the theoretical strengths.

No MeSH data available.


Related in: MedlinePlus